BRAFV600E mutation does not predict lymph node metastases and recurrence in Chinese papillary thyroid microcarcinoma patients
- 28 March 2024
- journal article
- research article
- Published by Elsevier in Oral Oncology
- Vol. 152, 106755
Abstract
No abstract availableKeywords
Funding Information
- National Health Commission of the People's Republic of China
This publication has 58 references indexed in Scilit:
- Population‐based study evaluating and predicting the probability of death resulting from thyroid cancer among patients with papillary thyroid microcarcinomaCancer Medicine, 2019
- Association of Lymph Node Density With Survival of Patients With Papillary Thyroid CancerJAMA Otolaryngology–Head & Neck Surgery, 2018
- Overall Survival of Papillary Thyroid Carcinoma Patients: A Single‐Institution Long‐Term Follow‐Up of 5897 PatientsWorld Journal of Surgery, 2018
- Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013JAMA, 2017
- BRAF (V600E) mutation analysis on liquid‐based cytology‐processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinomaCancer Cytopathology, 2012
- The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancerCancer, 2011
- An Observational Trial for Papillary Thyroid Microcarcinoma in Japanese PatientsWorld Journal of Surgery, 2009
- Risk Factors for Nodal Metastasis and Recurrence Among Patients with Papillary Thyroid Microcarcinoma: Differences in Clinical Relevance Between Nonincidental and Incidental TumorsWorld Journal of Surgery, 2009
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocalityCancer, 2003